Share on StockTwits

PTC Therapeutics (NASDAQ:PTCT) has received an average rating of “Buy” from the nine ratings firms that are covering the stock, StockRatingsNetwork reports. Eight research analysts have rated the stock with a buy rating, The average 1-year price target among brokers that have issued ratings on the stock in the last year is $41.58.

Shares of PTC Therapeutics (NASDAQ:PTCT) traded up 1.57% on Tuesday, hitting $32.27. 65,427 shares of the company’s stock traded hands. PTC Therapeutics has a 1-year low of $13.15 and a 1-year high of $34.65. The stock’s 50-day moving average is $27.89 and its 200-day moving average is $25.35. The company’s market cap is $946.8 million.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.86) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.75) by $0.11. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.71 million. PTC Therapeutics’s revenue was down 75.5% compared to the same quarter last year. Analysts expect that PTC Therapeutics will post $-3.49 EPS for the current fiscal year.

A number of research firms have recently commented on PTCT. Analysts at Roth Capital raised their price target on shares of PTC Therapeutics from $34.00 to $43.00 in a research note on Monday, August 18th. They now have a “buy” rating on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of PTC Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $60.00 price target on the stock. Finally, analysts at Bank of America initiated coverage on shares of PTC Therapeutics in a research note on Tuesday, July 22nd. They set a “buy” rating and a $37.00 price target on the stock.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes.

Receive News & Ratings for PTC Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.